EMA Authorised: Hexacima (hepatitis B surface antigen;Diphtheria toxoid;Bordetella pertussis antigens Pertussis Toxoid Filamentous Haemagglutinin;poliovirus (inactivated) type 1 (Mahoney) type 2 (MEF-1) type 3 (Saukett);Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) conjugated to Tetanus protein;tetanus toxoid) — Sanofi Winthrop Industrie

View source ↗

Summary

The European Medicines Agency authorised Hexacima, a hexavalent vaccine combining hepatitis B surface antigen, diphtheria toxoid, pertussis antigens (pertussis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Hepatitis B
• Meningitis Caused By Haemophilus Influenzae Type
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• Hexacima

Snippet

Status: Authorised. Therapeutic area: Hepatitis B;Tetanus;Immunization;Meningitis, Haemophilus;Whooping Cough;Poliomyelitis;Diphtheria. MAH: Sanofi Winthrop Industrie. Decision date: 26/09/2025